https://www.selleckchem.com/products/hdm201.html
Background and aims Both type 2 diabetes and cardiovascular (CV) disease develops at a younger age in Asians and often have a higher risk of mortality. Both sodium-glucose co-transport-2 inhibitors (SGLT-2Is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown a significant reduction in CV end-points in CV outcome trials (CVOTs). Whether similar CV benefit exists in Asians, is not yet clearly known. Methods We systematically searched relevant medical database up to January 31, 2020 and retrieved all the dedicated CVOTs co
Like
Comment
Share
